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Physiologic Assessment of Fetal
Compromise: Biomarkers of Toxic
Exposure
by Lawrence D. Longo*
Understanding the physiologic andendocrinologic basisoffetaldevelopment is amajorgoal ofperinatal
biology. During the past decade a number oftechnological developments have allowed more precise eval-
uation of the fetus in utero and diagnosis of abnormalities. Despite these methodological achievements,
however, there are no specific biological markers currently available to indicate that exposure to a given
xenobiotic is associated with a cellular, subcellular, or pharmacodynamic event.
This paper evaluates the following issues: What are some ofthe unique physiologic and endocrinologic
features ofthe fetal milieu interieur? What problems are peculiar to fetal assessment? Ofwhat value are
techniques such as ultrasonography, amniocentesis, chorionic villus sampling, fetoscopy, and fetal blood
and tissue sampling for obtaining appropriate biomarkers? What are some examples of validated biom-
arkers and their applicability? What promising biomarkers are on the horizon? What are some of the
promising techniques such as the evaluation offetal body movements, breathing activity, electronic heart
rate monitoring, and nuclear magnetic resonance? How may molecular probes be of value as biological
markers of fetal compromise? What are some of the major research gaps and needs, and how should
research priorities be set?
Some ofthese topics are addressed. Moreover, the more general role(s) that various diagnostic methods
and biological markers can have in an understanding ofthe regulation offetal growth and differentiation
and the role ofxenobiotics in affecting the normal course of events are discussed.
Introduction
Life does not begin at birth. Prenatally, we are ex-
posed to a variety ofchemicals and drugs inadvertently
or deliberately administered to a pregnant woman. In
rare instances, such exposure results in a malformed
child. These cases naturally attract wide attention, gen-
erate compassion, and stimulate further research.
During recent years several technological develop-
ments give promise that birth defects will become even
more rare. These developments include increasing so-
phistication in the art and science offetal diagnosis and
methodological advances ingenetics, molecularbiology,
andtoxicology, whichallow evenearlierand moresubtle
alterations from normal to be detected. As an illustra-
tion of this progress, during the past decade or so, a
number of monographs have appeared, devoted to the
topic ofdrug effects on the developing organism (1-6),
and an even larger number ofarticles and volumes are
devoted to in utero diagnosis (7).
Despite a number of advances that give the appear-
ance that the field is moving quite rapidly into the
twenty-first century, many would regard these devel-
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opments and a deep appreciation and understanding of
the molecular basis of drug- or chemical-induced de-
velopmental abnormalities as occurringtoo slowly. This
article will review several issues, including the follow-
ing: What are some of the unique features of the fetal
milieu interieur? What problems are peculiar to fetal
assessment? Of what value are techniques such as ul-
trasonography, amniocentesis, chorionic villus sam-
pling, fetoscopy, and fetalblood and tissue sampling for
obtaining appropriate biomarkers? What are some ex-
amples ofvalidated biomarkers and or their applicabil-
ity? What promising biomarkers are on the horizon?
What are some ofthe promising techniques such as the
evaluation offetalbodymovements, breathingactivity,
electronic heart rate monitoring, and nuclear magnetic
resonance? How may molecular probes be of value as
biological markers of fetal compromise? What are the
major research gaps and needs, and how should re-
search priorities be set?
Unique Features of the Milieu
lnterieur
Several considerations ofthe differences between fe-
tal and adult biology are relevant to a consideration of
biological markers. From a cardiopulmonary stand-L. D. LONGO
point, the fetus maintains normal tissue oxygenation in
the face ofwhat would be considered pathologically low
arterial 02 tension in the adult by maintaining a cardiac
output over twice that of an adult on a per kilogram
basis. Some specifics of these differences are detailed
in Table 1.
The developing fetus is also unique from an endocri-
nologic standpoint (Table 2). In part this relates to the
interaction and interdependence of the maternal-pla-
cental-fetal complex, such that the extraembryonic
membranes contain certain key enzymes for the metab-
olism of steroids and prostaglandins that are absent or
present in only very low concentrations in the fetus,
while in turn the fetal adrenal and liver contain key
enzymes absent from the placenta. For instance, the
inner or fetal zone ofthe fetal adrenal cortex has a high
steroid sulfokinase activity [so that a major secretory
product is dehydroepiandosterone sulfate (DHEAS)],
while it is deficient in A5,3p-ol dehydrogenase/A4,5,3-
Table 1. Comparisons of fetal and maternal cardiovascular
functions.
Function Fetus Adult
Pao2 (torr) 25 100
PacO2 (torr) 48 40
pH 7.35 7.40
V02 (mLmin -kg-') 8 4
[Hb] (g dL-l) 17.5 11.5
Hematocrit (%) 55 35
02 content (mL -dL') 16 15.4
02 content (mM) 7 6.7
Blood volume (mL/kg) 130 80
Descending aorta pressure
(mm Hg) 45 95
Pulmonary artery pressure
(mm Hg) 45 15
Cardiac output (mL minn'kg-') 220a 100
Systemic vascular resistance Low High
Vascular compliance High Low
aCalculated for both right and left ventricles.
Table 2. Hormones as potential biological markers.
Chorionic gonadotropin (hCG)
Chorionic somatomammotropin (hCS),
also called placental lactogen (also called hPL)
Other placental hormones (SP1, PP5, ,13-PAM, PAPP-A, PAPP-B)
Prolactin (PRL)
Estrogens (E1, E2, E3)
Progesterone (P4)
a-MSH
I3-Endorphin
p-Lipotropin
Adrenocorticotrophic hormone (ACTH)
Cortisol (F)
Dehydroepiandosterone (DHEAS)
Renin-angiotensin
Arginine vasopressin
Arginine vasotocin
Atrial natriuretic peptides
Catecholamines (dopamine, norepinephrine, epinephrine)
Prostaglandins
Hormonal rhythms
ketosteroid isomerase (so that conversion of pregnen-
olone to progesterone is limited). DHEAS is trans-
ported to the placenta, where it is hydrolyzed by a ste-
roid sulfatase and aromatized to estradiol-17,B, and to
the liver where it is 16-hydroxylated. Thus, DHEAS
serves as asubstrate forplacental estrone and estradiol
biosynthesis, hormones that probably are very impor-
tant in mediating many of the maternal adaptations to
pregnancy (8).
The fetal adrenalgland also produces relatively large
amounts of cortisol, which not only is important in the
maturation ofthe lung, pancreas, and otherorgans, but
also initiates a cascade of hormonal events (including
decreased progesterone and increased estrogen pro-
duction, and increased synthesis of prostaglandins by
extraembryonic tissues) involved in the initiation ofla-
bor. The stimuli forfetal adrenal hormone synthesis are
not elucidated. Although fetal adrenocorticotropin
(ACTH) plays a role, other pro-opiomelanocortin
(POMC)-derived peptides and several growth factors
are probably also important.
In addition to the features ofthe maternal-placental-
fetal complex there are several endocrine systems
unique to fetal life. These include the paraaortic chro-
maffin system active in catecholamine synthesis; the
fetal intermediate pituitary, which secretes a-melano-
cyte-stimulating hormone and I-endorphin; the poste-
rior pituitary, which secretes arginine vasotocin in ad-
ditiontovasopressin; theplacentalproductionofseveral
polypeptides [chorionic gonadotropin (hCG) and cho-
rionic somatomammotropin (hCS), also called placental
lactogen(hPL)]; andahalf-dozenorsootherpregnancy-
specific proteins (9), including several pituitarylike hor-
mones and neuropeptides.
The fetus develops in an environment where respi-
ration, alimentation, and excretory functions are pro-
vided by the placenta. About one-halfofits fuel supply
for tissue metabolism is for anabolism, and its growth
and differentiation are regulated by growth factors.
Potentially, many of these hormones and other poly-
peptides may serve as biological markers. Certainly,
various chemicals and toxins may act on the fetal hy-
pothalamus, adrenal, placenta, and other tissues to in-
hibit specific enzymes and metabolic pathways, thus al-
tering the synthesis of, and response to, various
hormones and growth factors. Nonetheless, it remains
to be demonstrated to what extent this inhibition oc-
curs.
Problems Unique to the Fetus
Clearly, optimal fetal development (growth and dif-
ferentiation) with survival as a newborn infant is the
only marker of fetal biology that assesses the effect of
toxic agents on the fetus as a whole. Nonetheless, bio-
markershaveobviouspotentialforthedevelopingfetus,
although a number ofproblems make their use fraught
with difficulty (Table 3). For instance, the fetus is not
quite as accessible as one might sometimes wish, and
obtaining fetalcells, tissue, oramniotic fluid formarker
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Table 3. Unique problems ofthe use offetal biomarkers.
Accessibility
Hormonal differences
Metabolic differences
Species differences
Gestational age
Litter size
Mass in relation to mother
Maturity at birth
determination can be fraught with difficulty. Despite
this relative inaccessibility, one can measure a number
of fetal physiologic variables, but most of these are
rather nonspecific, imprecise, and insensitive as mark-
ers of toxicity. Also, there are major hormonal differ-
ences between the fetus and adult (some of which can
be used to advantage) and differences in metabolism. A
further complication is that fetal responses can vary
widely among species, so that a given marker in one
species may not have application to other species. Ad-
ditionally, the fetus consists ofamultitude ofcelltypes,
each with unique responses to various agonists, and the
reactions ofthe several cells and tissues can vary with
their maturity and the stage ofdevelopment. As a cor-
ollary, the fetal maturity for the various species can
vary widely at birth. In addition, while much is known
of the effects of various chemicals and toxins, little is
known of the critical levels, critical periods during de-
velopment, or how biological variation affects the var-
iousresponses. Afinalproblemisthatalthoughonemay
observe and measure rathergross effects, there are few
indices ofmore subtle cellular and subcellular changes.
In light ofthese considerations, this review will focus
on individual components of the fetal system, i.e., or-
gan, tissue, and cell, and consider how biological mark-
ers might serve at several hierarchical levels as indices
of exposure or toxic effect.
Validated Techniques for Biological
Markers
Ultrasonography
Ofthetools currentlybeingusedsuccessfullyforfetal
diagnosis, fewhaveattractedtheattention ofdiagnostic
ultrasound. During the past decade, the limits of res-
olution ofantenatal ultrasound have increased dramat-
ically from the detection ofgross defects such as anen-
cephaly to subtle abnormalities ofthe fetal brain, heart
and vascular system, kidneys, and other organs (Table
4) (10). The accuracy ofhigh-resolution ultrasound is of
course the critical issue. Anencephaly can be diagnosed
with 100% certainty (11). Anomalies (such as alobar
holoprosencephaly with absent midline cerebral struc-
tures and related hypotelorism) manifested by two or
more embryologically related markers, each ofwhich is
detectablebyultrasound, canbediagnosedreliably(12).
This is in contrast to the accuracy in instances ofsingle
abnormalities of dimension (such as microcephaly) or
those in which the structure of interest is visualized
Table 4. Diagnostic ultrasound and biological markers.
Fetus Placenta
Maturational or morphometric biomarkers
Gross malformations Size
Estimated fetal weight Maturity
Head: biparietal diameter,
circumference
Abdomen: circumference
Head/abdomen: circumference
Femur: length
Heart: R/L ventricle, malformations
Functional or physiological biomarkers
Brain: cerebral blood flow Blood flow: uterine
Cardiovascular: heart rate, cardiac
output, umbilical blood flow,
umbilical systolic/diastolic Blood flow: umbilical
Respiratory: breathing movements,
somatic movements
inconsistently. Unfortunately, althoughinstrumentres-
olution and operator skill have improved, few studies
have rigorously examined the diagnostic accuracy for
various anomalies.
An area in which ultrasound has advanced rapidly is
in the diagnosis offetal size, and it is hoped, maturity.
Forinstance, certainmorphometricmeasurementshave
been found to be useful, including biparietal diameter
and circumference of the head, abdominal circumfer-
ence, and the length ofthe femur and otherlongbones.
Ultrasound is of value in the diagnosis offetal heart
defects and cardiovascular function (13). Combining
real-time with static techniques (so-called M mode) has
alloweddetectionofcardiacmorphology, rhythm, cham-
ber size, and pericardial effusion (13). In addition,
pulsed Doppler technology allows the measure of ve-
locitythrough cardiac valves and inmajorvessels. Dop-
pler technology, combined with measure of diameter,
permits acalculation ofcardiac output and/orblood flow
rate. More than 20 major malfunctions and malforma-
tions, including those of the genitourinary tract and
other systems, are diagnosable with these techniques
(14).
In addition to its diagnostic potential per se, ultra-
sound enhances the safety and effectiveness of other
diagnosticmethods such as amniocentesis, chorionic vil-
lus sampling, fetoscopy, and fetal blood sampling (15-
17).
Amniocentesis
The ability to enter the amniotic cavity without ap-
preciable risk to either mother or fetus has remarkably
influenced obstetric care. Aspiration ofa sample ofam-
niotic fluid allows a number of diagnostic tests to be
performed that are indicative of fetal well-being. Ini-
tially, amniocentesis was employed to estimate the con-
centration of bilirubin (and related pigments) in am-
niotic fluid, and thereby identify hemolytic disease.
Currently, amniocentesis is primarly used later in ges-
tation to determine the relative concentration of sur-
factant-activephospholipidsreleasedfromthefetallung
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in an effort to assess the risk of a premature infant
developing respiratory distress syndrome. In addition
to allowing quantification ofbilirubin concentration, the
lecithin-to-sphingomyelin ratio, andindividualphospho-
lipids such as phosphotidyl glycerol, amniocentesis is
becoming increasingly useful to identify a number of
hereditary disorders. Measurement of abnormal bio-
chemical processes has proven useful in the antenatal
diagnosis ofabout 100 inborn errors ofmetabolism. Es-
sentially all chromosomalanomalies, i.e., trisomy21,13,
and 18, and triploidy, are diagnosable from amniotic
fluid samples (18,19). Also, cx-fetoprotein levels can be
measured in amniotic fluid and can suggestthe presence
of neural tube defects, congenital nephrosis, and tri-
somy 21 (20). In addition, analysis ofcells from amniotic
fluid may be used for the antenatal diagnosis of chro-
mosomal abnormalities, genetic enzymatic defects, and
DNA adducts.
Chorionic Villus Sampling
As with amniocentesis, this relatively new technique
allows one to obtain cells that reflect the genetic con-
stitution of the conceptus. Used during weeks 8 to 12
ofthe first trimester, diagnostic results from chorionic
villus sampling are available within a few days to 2
weeks. Most commonly, a small sample ofchorionic villi
is aspirated through a flexible catheter which is passed
through the cervix under sonographic guidance (21).
Alternatively, an aspiration needle can bepassed trans-
abdominally (22). As with cells obtained via amniocen-
tesis, the diagnosis of hereditable disorders may be
made by enzyme assays, chromosome number or ab-
normality, and DNA analysis (Table 5) (23).
Several problems make chorionic biopsy more com-
plicated than amniocentesis. The risk ofinterruption of
pregnancy is not insignificant. In addition, contamina-
tion of the villi with maternal decidua is possible. Fi-
nally, in chorionic villi, chromosomal mosaicism appears
to be more common than in amniotic fluid cells (19).
Table 5. Chorionic villus sampling.a
Enzyme analysis Cytogenetic analysis
Tay-Sachs disease Normal male (46XY)
Adreno-leukodystrophy Normal female (46XX)
Farber's disease Trisomy
GM, gangliosidosis Translocation
Hunter's syndrome Mosaic
Hurler's syndrome Triploidy
Infantile Gaucher's disease Inversion
Lesch-Nyhan syndrome Sex chromosome abnormality
Menke's syndrome
Metachromatic leukodystrophy
Methylmalonic aciduria
Niemann-Pick disease
Sanfilippo's syndrome
Wolman's syndrome
Zellweger's syndrome
aFrom Jackson (23).
Fetoscopy
Considerable interest exists in instrumentation that
allowsdirectvisualizationofthefetusandplacentawith-
out the risk of disrupting the pregnancy (24). The pos-
sibility ofdirect visualization ofexternally located fetal
anomalies and the ability to sample directly tissue from
the fetus or fetal blood vessels in the umbilical cord or
placentawithout appreciable riskto the fetus ormother
holds greatpromise forthe detection ofbiologicalmark-
ers, whether specific compounds per se, DNA adducts,
or by the use of DNA probes. Currently, however, fe-
toscopy is a research procedure carried out in only a
few academic institutions.
Fetal Blood and Tissue Sampling
Fetal blood obtained in utero can be used for the
antenatal diagnosis ofhemoglobinopathies, coagulation
defects, metabolic and cytogenetic disorders, immuno-
deficiencies, and infections (25,26). Originally, such
specimens were collected by direct visualization ofum-
bilical or placental vessels through a fetoscope. More
recently, percutaneous samplingoffetalcordbloodwith
use ofa needle under sonographic guidance has allowed
fetal blood sampling with less risk to the unborn infant.
The availability of this blood permits the diagnosis of
many conditions and the detection of various biological
markers (16).
Fetal skin and liver have been sampled successfully
and used for histologic and biochemical studies when
amniocentesis or fetal blood sampling could not provide
the necessary information. Biopsy instruments have
been introduced under both fetoscopic and ultrasound
guidance to coliect these samples. Although classicaliy
genetic disorders (such as epidermolysis and ichthyosis
of the skin and glycogen storage disease and ornithine
transcarbamoylase deficiency of the liver) have been
diagnosed by this method, the tissue may be used for
study with DNA probes, etc.
Examples of Validated Markers
There are a number ofbiomarkers, the use ofwhich
has been validated in conjunction with the techniques
previously outlined. Some of these markers are of ex-
posure, some of clinical effect, and some help to eluci-
date molecular mechanisms. Classic case studies have
been presented on prenatal exposure tomethylmercury
(27,28), lead (29), fetalalcohol (30) and fetaltobacco (31)
syndromes, and others.
Promising Markers
Markers for Chemical and Environmental Terato-
gens. Prior to about 1960, the vast majority of birth
defects were regarded as genetic in origin. The fetus
was believed to occupy a privileged site within the
uterus, protected from the effects of environmental
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agents to whichthe mothermight be exposed. Although
association between maternal rubella infection and ab-
normal fetal development was recognized in the early
1940s, not until 20 years later did reports suggest that
prenatal exposure tothedrugthalidomide wasthe cause
of serious developmental defects. Since then a host of
chemicals, drugs, and environmental agents have been
implicated as teratogens. Thus, the pendulum has
swung the opposite direction, so that virtually every
drug and chemical is suspected of being the cause of a
congenital malformation. Table 6 lists some chemical
teratogens, classified by their relationshiop to fetal ab-
normalities (3,32,33). Some drugs have potential ad-
verse effects on the fetus, other drugs have a question-
Table 6. Relationship of chemical teratogens to fetal
abnormalities.a
Effect
Definite relationship
Probable relationship
Compound
Alcohol
Diphenylhydantoin
Folic acid antagonists
Inorganic iodides
Lithium
Organic mercury
Retinoids--Vitamin A, Acutane
Sex steroids (including
diethylstilbestrol)
Streptomycin
Tetracycines
Thalidomide
Thiourea compounds
Trimethadione
Warfarin
Alkylating agents
Chlorobiphenyls
Diazepam
Kanamycin
Questionable relationship Amphetamines
Chlordiazepoxide
Clomiphene
Diphenhydramine
Ethionamide
General anesthesia (chronic exposure)
Gonadotropins
Haloperidol
Lysergic acid diethylamide (LSD)
Meprobamate
Metronidazole
Oral hypoglycemic agents
Penicillamine
Phenothiazines
Quinine
Cigarette smoking
No relationship Bendectin
Corticosteroids
General anesthesia (short-term
exposure)
Heparin
Isoniazid
Meclizine
Penicillin
Spermatocides
Sulfonamides
aFrom Jones and Chernoff (32); Shepard (35); and Simpson et al.
(33).
able relationship to fetal anomalies, while for others,
including several classed as "litogens" (34), no relation-
ship to fetal abnormalities has been demonstrated (Ta-
ble 6). Table 7lists somedrugs withpotentially adverse
effects on the newborn infant.
Because of a number of circumstances, the vast ma-
jority of pregnant women are exposed to a variety of
agents. The scope of the problem is mind boggling, as
illustrated by the NIH Collaborative Perinatal Study
finding that the average pregnant woman takes five
drugs (including nutritional supplements) during the
course ofher pregnancy, and about one-halfofthe total
drug consumption occurs during the period of organo-
genesis, i.e., duringthe first trimester (3,35). Although
only 2 to 3% ofdevelopmental defects are known to be
due to drugs and chemicals and 65% are of unknown
origin, one cannot be sanguine with these figures, for
the overwhelming size ofthis "unknown" category only
reflects ourignorance and stressesthe needformarkers
that will help to identify specific chemicals and their
relation to given defects.
Examples of environmental chemicals that can harm
the fetus and can be particularly troublesome because
of their ubiquity and unsuspected presence are chlor-
biphenyls, laboratory solvents, hapthalene, and organic
mercury. Again, the need for biomarkers of exposure/
effects for these and other chemicals is enormous.
Heat-ShockProteins. Heat-shockproteins are pro-
duced by many cells in response to hyperthermic, hy-
poxic, or chemical stress. These proteins are ofseveral
size classes (usually 20-100 kilodaltons), and are syn-
thesized by normal cells. Although the functional sig-
nificance of these polypeptides is unknown, some evi-
dence suggests that they aid in the cells' tolerance to
Table 7. Drugs with potential adverse effects on the neonate.
Drug Potential adverse effect
Azathioprine Decreased immunologic
competence
Cannabis Neurobehavioral abnormalities
Chloramphenicol Gray syndrome
Diazepam Floppy Baby syndrome
Heroin Pre- and postnatal growth
retardation, microcephaly
Hexamethonium Paralytic ileus
Lithium Cardiac malformations
Naphthalene Hemolysis (G6PD deficiency)
Narcotics addiction (cocaine,
etc.) Withdrawal
Nitrofurantoin Hemolysis (G6PD deficiency)
Oxytocin Hyperbilirubinemia
Phenobarbital (excess) Neonatal bleeding
Propranolol Hypoglycemia and bradycardia
Quinine Thrombocytopenia
Reserpine Nasal congestion
Salicylates Platelet dysfunction
Cigarette smoking Intrauterine growth
retardation
Sulfonamides Hyperbilirubinemia
Thiazides Thrombocytopenia and
electrolyte imbalance
Warfarin Bleeding disorders
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excessive temperature and other stress. Several tera-
togens, including diphenylhydantoin, diethylstilbestrol,
griseofulvin, and coumarin, have been demonstrated to
result in the synthesis of certain proteins of the heat
shock class by amniotic fluid cells (36). Potentially, spe-
cific polypeptides for these or other toxins may be pro-
duced by cells in amniotic fluid or fetal blood, which
could be quantified by appropriate radioimmunoassays.
Promising Techniques for Biological
Markers
Fetal Body and Breathing Movements
Normally, during the second half of pregnancy, ex-
pectant mothers are cognizant of frequent movements
by the fetus. In normal pregnancies such movements
increase in number from about 30 per 12 hr at 24 weeks
ofgestation to about 130 at32weeks, and then to about
100 atterm; however, there is considerable normal var-
iation in these values (37). The fetus that moves con-
sistently is usually healthy. In contrast, a sudden de-
creaseinthisactivityisanominous signsuggestingfetal
compromise. In those instances of cessation of fetal
movements, the fetus often dies within the next 24 hr
(38). Decreasesinfetalmovementshavebeenassociated
with hypoxia and other conditions.
Fetal breathing activity can be detected by ultrason-
ographyand othertechniquesby 11 weeks. By 16weeks
these breathing movements are sufficiently intense to
move small amounts of amniotic fluid in and out of the
respiratory tract. During the third trimester, such
movements average about 50/min and are episodic. In
sheep, much of the activity occurs in association with
periods of rapid eye movements and high frequency,
low voltage, electrocortical activity (39). The frequency
of fetal breathing movements decreases in association
with hypoxemia, asphyxia, hypoglycemia, maternal
smoking, ethanol ingestion, and other stresses. Thus,
these breathing and body movements are an index of
fetal well-being. Changes in these functions, however,
are rather nonspecific and thus are rather crude biolog-
ical markers.
Electronic Fetal Heart Rate Monitoring
Antepartum and intrapartum surveillance of fetal
well-being with early detection offetal distress is most
commonly accomplished by monitoring the fetal heart
rate. During uterine contractions, uteroplacental blood
flow temporarily decreases. In instances of fetal com-
promise by intrinsic fetal disease, placental insuffi-
ciency, umbilical cord compression, maternal disease,
maternal hypoxemia orhypotension, or the administra-
tion ofcertain drugs, the heart rate will decrease, usu-
allyduringorafteracontraction. Inaddition, there may
be a decrease or loss of the normal beat-to-beat heart
rate variability.
The field offetal heart rate monitoringhas developed
an extensive literature with its own terminology. Un-
fortunately, the wealth of empirical observations and
associations has not been matched by a deep under-
standing ofthe physiologic basis forthe phenomena ob-
served. Although ofproven usefulness in the detection
offetal distress, changes in heart rate and beat-to-beat
variability are sufficiently nonspecific as to make their
role as biomarkers of limited value.
Biophysical Profile
Evaluation of several parameters of fetal well-being
have been combined into the biophysical profile. By the
use ofelectronic monitoring, fetal heart rate reactivity
is determined, and with diagnostic ultrasound, fetal
grossbodymovements, muscletone, breathingactivity,
and amniotic fluid volume are evaluated with an Apgar-
like score (40). Again, although apparently ofvalue em-
pirically, each index is nonspecific and of diagnostic
value in only a limited sense.
Nuclear Magnetic Resonance
Organ andtissue imagingusingnuclearmagnetic res-
onance (NMR) is becoming available in tertiary and
many other medical centers. Several reports of this
technique during pregnancy suggest its usefulness (41-
43); however, the safety of the procedure during ges-
tationhasyettobeestablished. Thehighmagneticfields
required could potentially affect embryonic and fetal
development, particularly in pregnant individuals who
work with the instrument on a long-term basis. In ex-
perimental animals the use of 31P-NMR to determine
functional metabolic correlates, temporal relationships,
and intracellular actions of chemicals in organs such as
the heart, liver, and placenta has great potential. The
use ofparamagnetic ions for specific visualization ofthe
placenta and conceptus may have limited application
(44).
Molecular Probes
Perhaps one ofthe most exciting emergingnew areas
of antenatal diagnosis is the use of DNA probes that
reveal genetic markers near specific genes (19). For
instance, just during the past year, DNA probes have
been applied to the prenatal diagnosis ofcystic fibrosis,
and predictive testing began for individuals who might
carry the gene for Huntington's disease (Table 8). In
addition, a portion of the gene for Duchenne muscular
dystrophy was isolated, and the recessive oncogene re-
sponsible for familial predisposition to retinoblastoma
was discovered. Such a genetic marker is a segment of
DNA that lies near a disease gene that has not been
identified. Ininstanceswherethemarkerisconsistently
inherited by victims of the disease, it signals that the
defective gene must be near the marker. Potentially,
with DNA probes and genetic markers it would be pos-
sible to detect most of the more than 3000 conditions
caused by single gene mutations. Recent advances in
the amplification ofdesired DNA sequences by as much
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Table 8. Disorders diagnosable by analysis of cellular DNA.
Validated
Sickle cell anemia
13-Thalessemia
a-Thalessemia
Factor VIII deficiency
Factor IX deficiency
Phenylketonuria
a-Antitrypsin deficiency
Huntington's disease
Antithrombin III deficiency
Ornithine transcarbamoylase
deficiency
Duchenne's muscular dystrophy
Argininosuccinic acid
dehydrogenase deficiency
Osteogenesis imperfecta type II
Congenital adrenal hyperplasia
Probable
Fragile X syndrome
Adult onset polycystic kidney
disease
as a millionfold make such sequences much easier to
detect.
The applications ofmolecular biology to clinical med-
icine will drastically change the approach to the diag-
nosis ofdisease (19). Unique sequence DNAprobes and
probes for restriction-fragment-length polymorphisms
are being generated at an ever increasing rate. Within
a few years, all monogenetic human diseases will have
molecular determinants, so that clinical diagnosis will
radically change from an emphasis on phenotype to that
of molecular genotype. Molecular diagnosis, even dur-
ingprenatal life, is possible bythe use ofthree different
but related techniques, e.g., restriction enzymes, oli-
gonucleotide probes, and restriction-fragment-length
polymorphisms (RFLPs). Briefly, highly specific re-
striction endonucleases cut DNA at certain base se-
quences. When altered by mutation, the DNA is sev-
ered into fragnments of a size different from normal. For
instance, in sickle cell anemia the mutation results in
loss of a restriction enzyme recognition site, so that the
resulting single DNA fragment is the size of the two
fragments from a normal beta-globin gene. The homo-
zygous (SS) and heterozygous (SA) states of sickle cell
anemia can be differentiated by this method. Abnor-
malities of the genes for growth hormone and 21-hy-
droxylase (the deficiency ofwhich results in congenital
adrenal hyperplasia) are examples of other conditions
diagnosable by this approach.
In instances where the precise DNA mutation is
known but the mutation is not discriminate for a re-
striction enzyme cut, oligonucleotide probes represent-
ing the normal and abnormal sequences may be used to
identify normals, heterozygotes, and homozygotes for
the mutation in question. Asincreasing numbers ofnor-
mal and mutated gene sequences are identified, the
practicality ofthis technique will increase. Restriction-
fragment-length polymorphisms, the third tool to be
developed, has been used to diagnose a number of con-
ditions, including Huntington's disease, phenylketonu-
ria, factor VIII and IX deficiencies, and some cases of
beta thalassemia.
The versatility of the DNA technology is enormous,
since a condition such as congenital adrenalhyperplasia
potentially may be diagnosed by any one ofthese three
methods. As increasing numbers of these polymorph-
isms are recognized and restriction enzymes are devel-
oped, every monogenetic disorder is potentially diag-
nosable by this technique. As the molecular map ofthe
humangenomeiscompleted, functionalcorrelationswill
evolve that may provide insights into the basic patho-
genesis of most disorders, including those caused by
chemical mutagens and physical factors, e.g., irradia-
tion. The impact of molecular biology on clinical medi-
cine and diagnosis duringthe next decade isbeyond our
imagination. Presumably, all diseases and toxic condi-
tions will be defined inmolecularterms and diagnosable
from a few microliters of blood. This scenario may be
upon us before we have the time to grasp the implica-
tions ofthis new technology (17).
Fromthestandpointofxenobiotics, DNAprobesmay
be used to detect chemical or food contaminants. Such
DNA-probe-based tests could replace current assays on
the basis thatthey are muchmore sensitive and require
less time to perform. R. Everson has reviewed the po-
tential use of DNA adducts in prenatal diagnosis else-
where in this volume (45).
A caveat should be noted regardingteststhatemploy
such DNA probes or DNA adducts. A potential pitfall
is that as these tests become more widely used, partic-
ularly ifcommercial kits become available, quality con-
trol may suffer. The assurance ofaccuracy is essential.
Reliability may suffer because of problems such as in-
complete DNA digestions, faulty hybridizations, con-
tamination, and mislabeling. Even in the best ofhands,
theinterpretationofthesetestsandtheassociatedcoun-
seling of families at risk require great experience and
commitment.
Finally, thereexiststheproblemofvalidationofthese
tests when no confirmatory assays exist. These and re-
lated issues accentuate the problemthat although these
revolutionary developments in DNA probes have enor-
mous potential as biomarkers in antenatal diagnosis,
many challenges lie ahead.
Research Gaps/Needs
When this committee was impaneled, we were given
several objectives: to identify and evaluate biological
processes that may yield useful markers, to develop
guidelines for the validation of biological markers, to
suggest strategies for the use of markers in human
health and environmental protection, and to identify
promising areas for future research on such markers.
Certainly, in terms of the fetus, each of these goals is
a major research need.
The use ofbiological markers to assess fetal risk pre-
sents a paradox. During the past decade a number of
techniques havebecomeavailablebothbyinvention and
improvement of existing methods. At the same time
increasing numbers of chemicals have been recognized
to have teratogenic and mutagenic potential. Nonethe-
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less, essentially no specific biomarkers are currently
available to indicate that exposure to agiven xenobiotic
is directly associated with a cellular, subcellular, or
pharmacodynamic event.
I would suggest, therefore, five major areas for re-
search. First, as has been voiced by many contributors
to this symposium, is the need for specific biological
markers. Whether chemical detection in fetal blood or
tissue, the extraembryonic membranes, amniotic fluid,
or maternal blood, or by the use of molecular tech-
niques, such biomarkers are essential. Second, valida-
tion of the accuracy, reliability, and predictability of
these markers will be required. Third is the need to
developnewapproaches andtechniques, includingmore
ready accessibility to the fetus. Fourth is the necessity
of developing strategies for the use of biomarkers for
protection ofthe fetus, and fifth is the requirement for
increased understanding of the fundamental mecha-
nisms whereby normal embryonic and fetal develop-
ment proceeds and howchemicals and otherxenobiotics
act on cellular and organ systems.
The achievement of these research goals will not be
easy, nor will they come cheaply. As with other great
efforts-the mapping ofthe human genome, the under-
standing ofthe molecular basis ofdisease, and the reg-
ulation ofgrowth and differentiation during normal de-
velopment-these objectives will require a major
research endeavor. In addition, the developments that
will allow the achievement ofthese goals cannot be pre-
dicted or planned by a committee. As with most sci-
entific advances, first-class discoveries only can origi-
nate from the minds of scientists unfettered by dogma
or preconceptions who are allowed free range for their
ideas.
In conclusion, the physiological assessment of fetal
compromise by markers oftoxic exposure is agoal wor-
thy of the biomedical research community. Priorities
need to be established regarding such research in hu-
mans and laboratory animals. Studies in pharmacoki-
netics and pharmacodynamics need to be conducted in
various organ systems, tissues, and cells.
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